First test for stem-cell institute -- money
By Jesse Reynolds,
San Francisco Chronicle
| 05. 15. 2005
Funding mechanism must avoid conflict of interest
The authors of last November's successful Proposition 71, the stem- cell research initiative, asked California voters to trust them in two distinct ways.
First, they convinced voters -- in some cases with shamelessly exaggerated promises about the imminence and likelihood of cures -- to invest $3 billion in research that has potential but is still at an early stage.
The second request was written into the initiative in print so fine that few voters had a chance of understanding it. Using obscure legalese, the initiative exempted the state agency it created, the California Institute for Regenerative Medicine, from many of the hard-won legal protections meant to ensure effective and transparent state governance. The result is that the institute, an agency entirely funded by the California public, is being run according to the practices of private enterprise. It best resembles a publicly funded, privately managed venture capital firm.
Now this experiment is facing a major obstacle. Lawsuits are challenging the constitutionality of Prop. 71's exclusion of public and legislative oversight. The state attorney general has determined that the bonds to fund...
Related Articles
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
By Ed Pilkington, The Guardian | 06.12.2026
Desperate US parents paying up to $20,000 a session for a procedure scientists say could be bogus
Autistic children as young as 18 months old are being injected with human stem cells derived from umbilical cords in unapproved, unproven and...
By Tobi Thomas, The Guardian | 06.10.2026
The UK’s stem cell transplant system is potentially putting the lives of blood cancer patients at risk as a result of inadequate infrastructure and a lack of long-term planning, a parliamentary report has found.
A hematopoietic stem cell transplant, often...